The effects of group 1 versus group 2 carbapenems on imipenem-resistant Pseudomonas aeruginosa: An ecological study

Diagnostic Microbiology and Infectious Disease

Volumn 70, Issue 3, 2011, Pages 367-372

  Carmeli, Yehuda ^a   Lidji, Shiri Klarfeld ^a   Shabtai, Esther ^a   Navon Venezia, Shiri ^a   Schwaber, Mitchell J ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Antibiotic resistance; Carbapenem; Ertapenem; Imipenem; Pseudomonas aeruginosa

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CEPHALOSPORIN DERIVATIVE; ERTAPENEM; IMIPENEM; MEROPENEM; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; IMIPENEM RESISTANT PSEUDOMONAS AERUGINOSA; ISRAEL; LONGITUDINAL STUDY; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; TEACHING HOSPITAL; TIME SERIES ANALYSIS;

ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; CARBAPENEMS; DRUG UTILIZATION; HUMANS; IMIPENEM; LONGITUDINAL STUDIES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDIES;

EID: 79959247071     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2011.03.009     Document Type: Article

References (32)

1. Aloush V., Navon-Venezia S., Seigman-Igra Y., Cabili S., Carmeli Y. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob. Agents Chemother. 2006, 50:43-48.
2. Brink A.J., Feldman C., Grolman D.C., Muckart D., Pretorius J., Richards G.A., Senekal M., Sieling W. Appropriate use of the carbapenems. S. Afr. Med. J. 2004, 94:857-861.
3. Burke J., Pestotnik S.L. The quality of antibiotic use and the quality of measuring it. Curr. Opin. Infect. Dis. 1997, 10:289-291.
4. Carmeli Y., Eichelberger K., Soja D., Dakos J., Venkataraman L., DeGirolami P., Samore M. Failure of quality control measures to prevent reporting of false resistance to imipenem, resulting in a pseudo-outbreak of imipenem-resistant Pseudomonas aeruginosa. J. Clin. Microbiol. 1998, 36:595-597.
5. Carmeli Y., Eliopoulos G.M., Samore M.H. Antecedent treatment with different antibiotic agents as a risk factor for vancomycin-resistant Enterococcus. Emerg. Infect. Dis. 2002, 8:802-807.
6. Carmeli Y., Troillet N., Eliopoulos G.M., Samore M.H. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob. Agents Chemother. 1999, 43:1379-1382.
7. Colodner R., Samra Z., Keller N., Sprecher H., Block C., Peled N., Lazarovitch T., Bardenstein R., Schwartz-Harari O., Carmeli Y. First national surveillance of susceptibility of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. to antimicrobials in Israel. Diagn. Microbiol. Infect. Dis. 2007, 57:201-205.
8. Cosgrove S., Carmeli Y. The impact of antimicrobial resistance on health and economic outcomes. Clin. Infect. Dis. 2003, 36:1433-1437.
9. Crank C., Hota B., Sebreti J. Effect of ertapenem utilization on Pseudomonas aeruginosa susceptibility to imipenem 2006, Poster 285.
10. de Oliveira A., Ciosak S.I., Ferraz E.M., Grinbaum R.S. Surgical site infection in patients submitted to digestive surgery: risk prediction and the NNIS risk index. Am. J. Infect. Control 2006, 34:210-217.
11. DiNubile M.F., Friedland I.R., Chan C.Y., Motyl M.R., Giezek H., McCarroll H.K., Shivaprakash M., Quinn J., Weinstein R., Chow J. Bowel colonization with vancomycin-resistant enterococci after antimicrobial therapy for intra-abdominal infections: observations from 2 randomized comparative trials of ertapenem therapy. Diagn. Microbiol. Infect. Dis. 2007, 58:491-494.
12. DiNubile M., Chow J.W., Vilas S., Polis A., Motyl M.R., Abramson M.A., Teppler H. Acquisition of resistant bowel flora during a double-blind randomized clinical trial of ertapenem versus piperacillin-tazobactam therapy for intraabdominal infections. Antimicrob. Agents Chemother. 2005, 49:3127-3221.
13. DiNubile M., Friedland I., Chan C.Y., Motyl M.R., Giezek H., Shivaprakash M., Weinstein R.A., Quinn J.P. Bowel colonization with resistant gram-negative bacilli after antimicrobial therapy of intra-abdominal infections: observations from two randomized comparative clinical trials of ertapenem therapy. Eur. J. Clin. Microbiol. Infect. Dis. 2005, 24:443-449.
14. Goff D.A., Mangino J.E. Ertapenem: no effect on aerobic gram-negative susceptibilities to imipenem. J. Infection. 2008, 57:123-127.
15. Goldstein E., Citron D.M., Peraino V., Elgourt V., Meibohm A.R., Lu S. Introduction of ertapenem into a hospital formulary: effect on antimicrobial usage and improved in vitro susceptibility of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 2009, 53:5122-5126.
16. Hsueh P., Snyder T.A., Dinubile M.J., Satischandran V., McCarroll K., Chow J.W. In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). Int. J. Antimicrob. Agents 2006, 28:238-243.
17. Kaye K.S., Kanafani Z.A., Dodds A.E., Engemann J.J., Weber S.G., Carmeli Y. Differential effects of levofloxacin and ciprofloxacin on the risk for isolation of quinolone-resistant Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 2006, 50:2192-2196.
18. Livermore D., Mushtaq S., Warner M. Selectivity of ertapenem for Pseudomonas aeruginosa mutants cross-resistant to other carbapenems. J. Antimicrob. Chemother. 2005, 55:306-311.
19. Neuhauser M.M., Weinstein R.A., Rydman R., Danzier L.H., Karam G., Quinn J.P. Antibiotic resistance among gram-negative bacilli in US intensive care units. Implications for fluoroquinolone use. JAMA 2003, 289:885-888.
20. Niederman M. Reexamining quinolone use in the intensive care unit: use them right or lose the fight against resistant bacteria. Crit. Care Med. 2005, 33:443-444.
21. Paramythiotou E., Lucet J.C., Timsit J.F., Vanjak D., Paugam-Burtz C., Trouillet C.J.L., Belloc S., Kassis N., Karabinis A., Andremont A. Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity. Clin. Infect. Dis. 2004, 38:670-677.
22. Paterson D. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs). Clin. Infect. Dis. 2000, 6:460-463.
23. Paterson D. Collateral damage from cephalosporin or quinolone antibiotic therapy. Clin. Infect. Dis. 2004, 38(Suppl. 4):341-345.
24. Paterson D., Ko W.C., Von Gottberg A., Mohapatra S., Casellas J.M., Goossens H., Mulazimoglu L., Trenholme G., Klugman K.P., Bonomo R.A., Rice L.B., Wagener M.M., McCormack J.G., Yu V.L. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum b-lactamases. Clin. Infect. Dis. 2004, 39:31-37.
25. Quinn J., Dudek E.J., DiVincenzo C.A., Lucks D.A., Lerner S.A. Emergence of resistance to imipenem during therapy for Pseudomonas aeruginosa infections. J. Infect. Dis. 1986, 154:289-294.
26. Rodloff A., Goldstein E.J.C., Torres A. Two decades of imipenem therapy. J. Antimicrob. Chemother. 2006, 58:916-929.
27. Schwaber M.J., Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum {beta}-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J. Antimicrob. Chemother. 2007, 60:913-920.
28. Schwaber M.J., De-Medina T., Carmeli Y. Epidemiological interpretation of antibiotic resistance studies - what are we missing?. Nat. Rev. Microbiol. 2004, 2:979-983.
29. Shah P.M., Isaacs R.D. Ertapenem, the first of a new group of carbapenems. J. Antimicrob. Chemother. 2003, 52:538-542.
30. Stone S., Cooper B.S., Kibbler C.C., Cookson B.D., Roberts J.A., Medley G., Duckworth G., Lai R., Ebrahim S., Brown E. The ORION statement: guidelines for transparent reporting of outbreak reports and intervention studies of nosocomial infection. Lancet Infect. Dis. 2007, 7:282-288.
31. Tumbarello M., Sanguinetti M., Montuori E., Trecarichi E.M., Posteraro B., Fiori B., Citton R., D'Inzeo T., Fadda G., Cauda R., Spanu T. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob. Agents Chemother. 2007, 51:1987-1994.
32. Weber S.G., Gold H.S., Hooper D.C., Karchmer A.W., Carmeli Y. Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg. Infect. Dis. 2003, 9:1415-1422.